The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 27997164 |
18 |
Synthesis of Novel c(AmpRGD)-Sunitinib Dual Conjugates as Molecular Tools Targeting thea |
Universit£ |
| 27774126 |
95 |
Exploring |
University Of California San Francisco |
| 26753814 |
7 |
Cyclic RGD peptidomimetics containing 4- and 5-amino-cyclopropane pipecolic acid (CPA) templates as dualaVß3 anda5ß1 integrin ligands. |
University Of Florence |
| 24949551 |
22 |
Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides. |
Philipps-Universit£T Marburg |
| 24973662 |
8 |
Targeting integrinsavß3 anda5ß1 with newß-lactam derivatives. |
University Of Bologna |
| 24654918 |
19 |
Pharmacophoric modifications lead to superpotentavß3 integrin ligands with suppresseda5ß1 activity. |
Technische Universit£T M£Nchen |
| 24412498 |
15 |
Synthesis and assay of retro-a4ß1 integrin-targeting motifs. |
University Of Bologna |
| 24095096 |
3 |
Synthesis and in vitro evaluation of a novel radioligand foravß3 integrin receptor imaging: [18F]FPPA-c(RGDfK). |
University Hospital Of Geneva |
| 23811088 |
26 |
Modulation ofavß3- anda5ß1-integrin-mediated adhesion by dehydro-ß-amino acids containing peptidomimetics. |
University Of Bologna |
| 23562062 |
4 |
Arylsulfonamide pyrimidines as VLA-4 antagonists. |
Elan Pharmaceuticals |
| 23376251 |
32 |
Towards dual antithrombotic compounds - balancing thrombin inhibitory and fibrinogen GPIIb/IIIa binding inhibitory activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism. |
University Of Ljubljana |
| 23362923 |
59 |
Biselectivity of isoDGR peptides for fibronectin binding integrin subtypesa5ß1 andavß6: conformational control through flanking amino acids. |
Technische Universit£T M£Nchen |
| 20088512 |
4 |
One step radiosynthesis of 6-[(18)F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester ([(18)F]F-Py-TFP): a new prosthetic group for efficient labeling of biomolecules with fluorine-18. |
University Of Troms£ |
| 19959360 |
50 |
SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonists. |
Jerini |
| 19910191 |
46 |
Discovery of orally available integrin alpha5beta1 antagonists. |
Jerini |
| 21601452 |
2 |
Tetrazine-trans-cyclooctene ligation for the rapid construction of integrinavß3 targeted PET tracer based on a cyclic RGD peptide. |
University Of Delaware |
| 21349709 |
6 |
Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging. |
Washington University |
| 20888763 |
8 |
Synthesis and evaluation of bivalent, peptidomimetic antagonists of theavß3 integrins. |
The Methodist Hospital Research Institute |
| 17289386 |
10 |
Inhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics. |
Universit£ |
| 16982193 |
26 |
Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening. |
Chinese Academy Of Medical Sciences And Peking Union Medical College |
| 16854058 |
8 |
Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents. |
University Of Southern California |
| 16722662 |
2 |
Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. |
University Of Naples Federico Ii |
| 16570923 |
8 |
Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. |
Washington University |
| 15715477 |
3 |
Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. |
University Of Southern California |
| 15369386 |
11 |
Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis. |
Merck Research Laboratories |
| 15863341 |
33 |
Non-peptidic alpha(v)beta3 antagonists containing indol-1-yl propionic acids. |
Johnson & Johnson Pharmaceutical Research And Development |
| 15357963 |
16 |
Nonpeptide alpha V beta 3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone. |
Merck Research Laboratories |
| 14521404 |
10 |
Docking studies on alphavbeta3 integrin ligands: pharmacophore refinement and implications for drug design. |
Technische Universit£T M£Nchen |
| 11020288 |
13 |
Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist. |
Merck Research Laboratories |
| 8893849 |
10 |
Synthesis and solution conformation of cyclo[RGDRGD]: a cyclic peptide with selectivity for the alpha V beta 3 receptor. |
Texas A&M University |
| 7650686 |
3 |
Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. |
Merck Research Laboratories |
| 15013021 |
10 |
Non-peptide alpha v beta 3 antagonists. Part 7: 3-Substituted tetrahydro-naphthyridine derivatives. |
Merck Research Laboratories |
| 12643914 |
40 |
Biphenyls as potent vitronectin receptor antagonists. Part 2: biphenylalanine ureas. |
Bayer |
| 14643310 |
6 |
Non-peptide alpha(v)beta(3) antagonists: identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint. |
Merck Research Laboratories |
| 12419389 |
13 |
Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacements. |
Merck Research Laboratories |
| 11755355 |
32 |
Biphenyls as potent vitronectin receptor antagonists. |
Bayer |
| 12161158 |
11 |
Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics. |
Merck Research Laboratories |
| 11992781 |
31 |
Synthesis of highly potent and selective hetaryl ureas as integrin alpha(V)beta3-receptor antagonists. |
Basf |
| 11738567 |
16 |
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements. |
Merck Research Laboratories |
| 11738566 |
20 |
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide. |
Merck Research Laboratories |
| 9873697 |
15 |
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model. |
Smithkline Beecham Pharmaceuticals |
| 23140358 |
28 |
Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrinaVß3. |
Universit£ |
| 22959246 |
24 |
Camptothecins in tumor homing via an RGD sequence mimetic. |
Sigma-Tau Industrie Farmaceutiche Riunite |
| 22871580 |
6 |
Near-infrared fluorescent divalent RGD ligand for integrinavß3-targeted optical imaging. |
Washington University |
| 22621422 |
2 |
¹²5I-radiolabeled morpholine-containing arginine-glycine-aspartate (RGD) ligand ofavß3 integrin as a molecular imaging probe for angiogenesis. |
University Of Florence |
| 22575869 |
61 |
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 1. |
Astrazeneca |
| 22572578 |
124 |
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 2. |
Astrazeneca |
| 20055426 |
30 |
Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics. |
Universita Degli Studi Di Bologna |
| 19860432 |
42 |
alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers. |
Universite Catholique De Louvain |
| 18343671 |
8 |
Synthesis, SAR and in vitro evaluation of new cyclic Arg-Gly-Asp pseudopentapeptides containing a s-cis peptide bond as integrin alphavbeta3 and alphavbeta5 ligands. |
Department Of Organic Chemistry Ugo Schiff University Of Firenze Via Della Lastruccia 13 |
| 18303826 |
48 |
Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. |
Universit£ |
| 18068982 |
20 |
Design and synthesis of novel potent and selective integrin alphanubeta3 antagonists--novel synthetic routes to isoquinolinone, benzoxazinone, and quinazolinone acetates. |
Basf |
| 17184884 |
16 |
Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design. |
Johnson & Johnson Pharmaceutical Research And Development |
| 16302808 |
28 |
Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. |
Universit£ |
| 15357991 |
20 |
Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands. |
3-Dimensional Pharmaceuticals |
| 12139455 |
78 |
Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents. |
Genentech |
| 9191954 |
9 |
Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists. |
Merck Research Laboratories |
| 10673106 |
28 |
RGD mimetics containing a central hydantoin scaffold: alpkha(v)beta3 vs alpha(IIb)beta3 selectivity requirements. |
Hoechst Marion Roussel |
| 22365562 |
154 |
Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold. |
University Of Ljubljana |
| 21344906 |
54 |
Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. |
The University Of Tokyo |
| 20951038 |
3 |
Small molecule inhibitors of hantavirus infection. |
University Of New Mexico School Of Medicine |
| 20809642 |
28 |
Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis. |
University Of Florence |
| 20218623 |
68 |
Emerging targets in osteoporosis disease modification. |
Amgen |
| 19942441 |
47 |
Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation. |
Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni |
| 19574045 |
44 |
Novel inhibitors of the alphavbeta3 integrin--lead identification strategy. |
Astrazeneca |
| 19195898 |
8 |
Morpholine-based RGD-cyclopentapeptides as alphavbeta3/alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity. |
Università |
| 19113865 |
6 |
Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. |
Stanford University School Of Medicine |
| 19081719 |
20 |
Synthesis and initial evaluation of novel, non-peptidic antagonists of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5). |
Pharmacopeia |
| 17244604 |
7 |
Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands. |
Cancer Research Uk Clinical Centre |
| 17973471 |
24 |
Multiple N-methylation by a designed approach enhances receptor selectivity. |
Technische UniversitäT MüNchen |
| 17910915 |
19 |
Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides. |
Bayer Healthcare |
| 17869121 |
32 |
Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds. |
Università |
| 17616113 |
63 |
Design and synthesis of a new class of selective integrin alpha5beta1 antagonists. |
Jerini |
| 17399986 |
114 |
R-isomers of Arg-Gly-Asp (RGD) mimics as potent alphavbeta3 inhibitors. |
Pfizer |
| 17387018 |
74 |
Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization. |
Pfizer |
| 16621534 |
87 |
Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists. |
Pfizer |
| 16509596 |
29 |
Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study of their conformational and biological behavior. |
Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni |
| 16303301 |
44 |
Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic properties. |
Pfizer |
| 16298127 |
80 |
Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists. |
Pfizer |
| 15974570 |
30 |
Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists. |
Università |
| 15745815 |
7 |
Nonpeptide alpha(v)beta3 antagonists: identification of potent, chain-shortened 7-oxo RGD mimetics. |
Merck Research Laboratories |
| 15715463 |
16 |
Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core. |
Johnson And Johnson Pharmaceutical Research & Development |
| 15501072 |
58 |
1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability. |
Johnson & Johnson Pharmaceutical Research & Development |
| 15380233 |
46 |
Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins. |
Johnson & Johnson Pharmaceutical Research And Development |
| 15125957 |
23 |
N-Aryl-gamma-lactams as integrin alphavbeta3 antagonists. |
Amgen |
| 15109653 |
30 |
Discovery of a potent and selective alpha v beta 3 integrin antagonist with strong inhibitory activity against neointima formation in rat balloon injury model. |
Dainippon Pharmaceutical |
| 15056002 |
112 |
Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists. |
Millennium Pharmaceuticals |
| 15006384 |
179 |
Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonists. |
Pfizer |
| 14741263 |
67 |
Solid-phase synthesis of a small library of 3-phenylthio-3-nicotinyl propionic acid derivatives acting as antagonists of the integrin alphaVbeta3. |
Nerviano |
| 14698164 |
39 |
Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds. |
Pharmaceutical Research Institute |
| 14640540 |
18 |
Molecular model of the alpha(IIb)beta(3) integrin. |
Merck Research Laboratories |
| 14561098 |
8 |
Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
Merck Research Laboratories |
| 12729670 |
49 |
Non-peptide alphavbeta3 antagonists. Part 6: design and synthesis of alphavbeta3 antagonists containing a pyridone or pyrazinone central scaffold. |
Merck Research Laboratories |
| 12668017 |
17 |
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists. |
Glaxosmithkline |
| 12565960 |
33 |
Thiophene-based vitronectin receptor antagonists. |
Shire Biochem |
| 12565923 |
6 |
Solid-phase synthesis of cyclic RGD-furanoid sugar amino acid peptides as integrin inhibitors. |
Leiden University |
| 12482416 |
52 |
Highly potent and selective alphaVbeta3-receptor antagonists: solid-phase synthesis and SAR of 1-substituted 4-amino-1H-pyrimidin-2-ones. |
Basf |
| 12477347 |
16 |
Binding model for nonpeptide antagonists of alpha(v)beta(3) integrin. |
Merck Research Laboratories |
| 12392735 |
30 |
Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists. |
Institut De Recherches Servier |
| 11855984 |
102 |
Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. |
Merck |
| 11814816 |
30 |
Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel potent and selective alpha(V)beta(3) antagonists. |
Knoll |
| 11714601 |
9 |
Discovery and evaluation of piperidinyl carboxylic acid derivatives as potent alpha(4)beta(1) integrin antagonists. |
Bayer |
| 11454469 |
95 |
alpha(v)beta(3) Antagonists based on a central thiophene scaffold. |
Aventis Pharma Deutschland |
| 11392539 |
34 |
Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes. |
Cor Therapeutics |
| 11384239 |
82 |
Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists. |
Technische UniversitäT MüNchen |
| 11327582 |
23 |
2-Acylimino-3H-thiazoline derivatives: a novel template for platelet GPIIb/IIIa receptor antagonists. |
Taisho Pharmaceutical |
| 10853677 |
34 |
Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists. |
Celltech Chiroscience |
| 10633037 |
88 |
Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3). |
Dupont Pharmaceuticals |
| 10633036 |
79 |
Isoxazolines as potent antagonists of the integrin alpha(v)beta(3). |
Dupont Pharmaceuticals |
| 10633035 |
20 |
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. |
Smithkline Beecham Pharmaceuticals |
| 10447947 |
14 |
N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. |
Technische UniversitäT MüNchen |
| 10406646 |
15 |
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. |
Smithkline Beecham Pharmaceuticals |
| 10406645 |
36 |
Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics. |
Smithkline Beecham Pharmaceuticals |
| 10230615 |
60 |
Rapid synthesis of RGD mimetics with isoxazoline scaffolds on solid phase: identification of alphavbeta3 antagonists lead compounds. |
Dupont Pharmaceuticals |
| 10197962 |
13 |
Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action. |
Dupont Pharmaceuticals |
| 9873696 |
80 |
Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists. |
Smithkline Beecham Pharmaceuticals |
| 9435900 |
89 |
Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors. |
Cor Therapeutics |
| 9288166 |
74 |
Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists. |
Eli Lilly |
| 9240343 |
28 |
Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists. |
Smithkline Beecham Pharmaceuticals |
| 8057299 |
66 |
Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. |
Merck Research Laboratories |
| 7507165 |
139 |
Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists. |
Telios Pharmaceuticals |
| 1469694 |
22 |
Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. |
Merck Research Laboratories |
| 28351594 |
24 |
New potent and selective?v? |
Jiangnan University |
Search and Browse
